RTW Biotech Opportunities Ltd (RTWFF) Q2 2025 Earnings Call Transcript

RTW Biotech Opportunities Ltd reported a 6% NAV per share decline for H1 2025, outperforming the Russell 2000 Biotech Index's 11.4% fall, demonstrating portfolio resilience. The company highlighted its consistent long-term outperformance against major biotech indices since its IPO, with its flagship fund achieving a 21% annualized return since 2009. RTW Bio's diversified portfolio, 70% public and 30% late-stage private, is strategically positioned to capitalize on deeply dislocated biotech valuations, accelerating M&A driven by large pharma's patent cliffs and significant cash flows from obesity drugs, and a stabilizing U.S. policy environment. Upcoming catalysts from key private holdings, coupled with recent share buybacks and impending FTSE All Share Index inclusion, underscore management's confidence and the perceived attractive entry point for investors.

Analysis

RTW Biotech Opportunities Ltd. (RTW) demonstrated portfolio resilience in H1 2025, with its NAV per share declining by 6%, which significantly outperformed the Russell 2000 Biotech Index's 11.4% fall. This performance is presented within a broader context of long-term outperformance against key biotech indices since its IPO, underpinned by a strategy focused on a diversified, full life-cycle approach. The portfolio is currently weighted 70% to public equities and 30% to late-stage private assets and royalties, with 85% of total holdings being either commercial or in late-stage development. Management's thesis rests on a deeply dislocated biotech sector, where many companies trade below cash, creating a prime opportunity for value creation. This is amplified by expectations of accelerating M&A activity, driven by large pharma's need to fill pipelines ahead of major patent cliffs and the record cash flows from obesity drug leaders like Eli Lilly and Novo Nordisk. Key portfolio contributors included Akero and UroGen, while detractors like Rocket and a 2.3% NAV drag from the private portfolio highlight individual asset risk. The fund has significant exposure (~15% of NAV) to the obesity theme through private holdings Corxel and Kailera, which face near-term clinical readouts. Furthermore, RTW's impending inclusion in the FTSE All Share Index and its active share repurchase program, which was 0.5% accretive to NAV in H1, are cited as potential tailwinds for the stock price.

Key Decisions for Investors

• Investors should consider the fund's significant discount to NAV, which management argues implies the private portfolio is being valued at a near-90% discount, as a potentially attractive entry point given its track record of outperformance and the bullish sector outlook.
• Closely monitor upcoming clinical data catalysts, particularly the Phase III results for Kailera and Corxel in obesity and stroke, as these two assets represent a concentrated 15% of NAV and are central to the fund's growth thesis.
• Evaluate the pace of the broader biotech market recovery, including the reopening of the IPO window and an increase in development-stage M&A, as these macro factors are critical for validating RTW's thesis and unlocking value in its late-stage portfolio.
• Note the potential for near-term share price support from the company's inclusion in the FTSE All Share Index and continued disciplined share buybacks, which management is using to address the discount to NAV.